{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:14:31Z","timestamp":1792300471206,"version":"4.4.0"},"reference-count":68,"publisher":"FapUNIFESP (SciELO)","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"abstract":"<jats:p>ABSTRACT In this review, we discuss the therapies used in the treatment of patients with Duchenne muscular dystrophy since the first description of the disease. A short description is given of the various theories based on disease pathogenesis, which give the substrates for the many therapeutic interventions. A brief review of the methods of evaluation used in therapeutic trials is made. Of all the treatments, the only drugs that are still considered able to modify the course of the disease are the corticosteroids (prednisone\/prednisolone\/deflazacort). Other drugs (coenzyme Q10 and creatine) have had a little effect in a few functions without adverse reactions. Idebenone seems to improve the respiratory function in the long term. The trials with mRNA transcription, through nonsense mutations or exon 51 skipping, show some beneficial results in a few functional tests, but they are limited to a small set of DMD patients.<\/jats:p>","DOI":"10.1590\/0004-282x20190088","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:23:08Z","timestamp":1567624988000},"page":"579-589","source":"Crossref","is-referenced-by-count":32,"title":["Duchenne muscular dystrophy: an historical treatment review"],"prefix":"10.1590","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-1038","authenticated-orcid":false,"given":"Lineu Cesar","family":"Werneck","sequence":"first","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4457-7771","authenticated-orcid":false,"given":"Paulo Jos\u00e9","family":"Lorenzoni","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-5074","authenticated-orcid":false,"given":"Renata Dal-Pr\u00e1","family":"Ducci","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-5376","authenticated-orcid":false,"given":"Otto Hern\u00e1ndez","family":"Fustes","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0173-0809","authenticated-orcid":false,"given":"Cl\u00e1udia Suemi Kamoi","family":"Kay","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-5317","authenticated-orcid":false,"given":"Rosana Herminia","family":"Scola","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2019,8]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JND-170280","article-title":"Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from TRET-NMD global database","volume":"4","author":"Koeks Z","year":"2017","journal-title":"J Neuromusc Dis"},{"issue":"R1","key":"ref2","first-page":"63","article-title":"Exon-skipping advances for Duchenne muscular dystrophy","volume":"R2","author":"Echevarr\u00eda L","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archneur.1987.00520200012009","article-title":"Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls","volume":"44","author":"Mendell JR","year":"1987","journal-title":"Arch Neurol"},{"issue":"1046","key":"ref4","first-page":"52","article-title":"Detecting meaningful changes using the North Star Ambulatory Assessment in Duchenne muscular dystrophy","volume":"55","author":"Mayhew AG","year":"2013","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/mus.880150316","article-title":"Long-term electrical stimulation of muscles in children with Duchenne and Becker muscular dystrophy","volume":"15","author":"Zupan A","year":"1992","journal-title":"Muscle Nerve"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/(SICI)1097-4598(199711)20:11<1422::AID-MUS10>3.0.CO;2-3","article-title":"Skeletal muscle fiber degeneration in mdx mice induced by electrical stimulation","volume":"20","author":"Yoshida M","year":"1997","journal-title":"Muscle Nerve"},{"key":"ref7","first-page":"20","article-title":"Therapeutic trials with galantamine in Duchenne-Griesinger-type progressive muscular dystrophy]","volume":"37","author":"Serafini L","year":"1961","journal-title":"Rass Clin Sci"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/jnnp.26.2.111","article-title":"A trial of therapy by nucleosides and nucleotides in muscular dystrophy","volume":"26","author":"Thomson WHS","year":"1963","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5414","key":"ref9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/bmj.2.5414.915","article-title":"Laevadosin in treatment of the Duchenne type of muscular dystrophy: preliminary results of a double-blind controlled trial","volume":"2","author":"Pearce JM","year":"1964","journal-title":"BMJ"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0026-0495(78)90161-0","article-title":"X-Linked recessive (Duchenne) muscular dystrophy (DMD) and purine metabolism: Effects of oral allopurinol and adenylate","volume":"27","author":"Thomson WHS","year":"1978","journal-title":"Metabolism"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1212\/WNL.35.1.61","article-title":"Chronic allopurinol and adenine therapy in Duchenne muscular dystrophy: effects on muscle function, nucleotide degradation, and muscle ATP and ADP content","volume":"35","author":"Bertorini TE","year":"1985","journal-title":"Neurology"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00198-010-1275-5","article-title":"Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment","volume":"22","author":"Bianchi ML","year":"2011","journal-title":"Osteoporos Int"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1212\/01.WNL.0000125178.18862.9D","article-title":"Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy","volume":"62","author":"Tarnopolsky MA","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ana.20523","article-title":"CINRG Group. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy","volume":"58","author":"Escolar DM","year":"2005","journal-title":"Ann Neurol"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0925-4439(95)00040-B","article-title":"Simonsen. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and nerogenic atrophies","volume":"1271","author":"Folkers K","year":"1995","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/mus.22047","article-title":"CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy","volume":"44","author":"Spurney CF","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref17","first-page":"6","article-title":"Online self-report data for Duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits","volume":"6","author":"Wang RT","year":"2014","journal-title":"PLoS Curr"},{"issue":"9979","key":"ref18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S0140-6736(15)60025-3","article-title":"Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial","volume":"385","author":"Buyse GM","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ajmg.1320100313","article-title":"Benigns Duchenne muscular dystrophy in a patient with growth hormone deficiency","volume":"10","author":"Zatz M","year":"1981","journal-title":"Am J Med Genet"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/jnnp.51.12.1551","article-title":"The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy","volume":"51","author":"Coakley JH","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/mus.880131212","article-title":"Randomized, double-blind trial of mazindol in Duchenne dystrophy","volume":"13","author":"Griggs RC","year":"1990","journal-title":"Muscle Nerve"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.nmd.2012.07.009","article-title":"Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure","volume":"22","author":"Rutter MM","year":"2012","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"ref23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.880110807","article-title":"Therapeutic trial of isaxonine in Duchenne muscular dystrophy","volume":"1","author":"Heckmatt JZ","year":"1988","journal-title":"Muscle Nerve"},{"issue":"8","key":"ref24","first-page":"41","article-title":"[Effect of sinestrol on the course of the myodystrophic process in progressive Duchenne muscular dystrophy]","volume":"89","author":"Zavadenko NN","year":"1989","journal-title":"Zh Nevropatol Psikhiatr Im S S Korsakova"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1212\/WNL.56.8.1075","article-title":"A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy","volume":"56","author":"Fenichel GM","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1212\/01.WNL.0000287070.00149.a9","article-title":"Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy","volume":"70","author":"Skura CL","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.25.12.1111","article-title":"Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber","volume":"25","author":"Mokri B","year":"1975","journal-title":"Neurology"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/WNL.28.5.439","article-title":"Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies","volume":"28","author":"Bodensteiner JB","year":"1978","journal-title":"Neurology"},{"issue":"8271","key":"ref29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(82)92063-3","article-title":"Verapamil in Duchenne muscular dystrophy","volume":"1","author":"Emery AE","year":"1982","journal-title":"Lancet"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mus.880090412","article-title":"A trial of flunarizine in the treatment of Duchenne muscular dystrophy","volume":"9","author":"Dick DJ","year":"1986","journal-title":"Muscle Nerve"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/mus.880100106","article-title":"Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine","volume":"10","author":"Moxley 3rd RT","year":"1987","journal-title":"Muscle Nerve"},{"issue":"13","key":"ref32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF01720830","article-title":"A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy","volume":"66","author":"Pernice W","year":"1988","journal-title":"Klin Wochenschr"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.38.4.609","article-title":"Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy","volume":"38","author":"Bertorini TE","year":"1988","journal-title":"Neurology"},{"issue":"4","key":"ref34","first-page":"CD004571","article-title":"Calcium antagonists for Duchenne muscular dystrophy","author":"Phillips MF","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"5436","key":"ref35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/247103b0","article-title":"Proximal myopathy induced by 5-HT-imipramine simulates Duchenne dystrophy","volume":"247","author":"Parker JM","year":"1974","journal-title":"Nature"},{"issue":"4","key":"ref36","first-page":"164","article-title":"Clinical trials of vasoactive and antiserotonin drugs in Duchenne muscular dystrophy","volume":"15","author":"Patten BM","year":"1983","journal-title":"Ann Clin Res"},{"issue":"17","key":"ref37","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0000000000004570","article-title":"Tadalafil DMD Study Group. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy","volume":"89","author":"Victor RG","year":"2017","journal-title":"Neurology"},{"issue":"Suppl 3","key":"ref38","first-page":"94","article-title":"A double-blind controlled trial of Penicillamine therapy in Duchenne muscular dystrophy: interim comments","volume":"70","author":"Bradley WG","year":"1977","journal-title":"Proc R Soc Med"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/mus.880111110","article-title":"Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E","volume":"11","author":"Fenichel GM","year":"1988","journal-title":"Muscle Nerve"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/WNL.0b013e31824c46be","article-title":"Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial","volume":"78","author":"Escolar DM","year":"2012","journal-title":"Neurology"},{"issue":"3 Pt 1","key":"ref41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.43.3_Part_1.520","article-title":"Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)","volume":"43","author":"Griggs RC","year":"1993","journal-title":"Neurology"},{"issue":"3 Pt 1","key":"ref42","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1212\/WNL.43.3_Part_1.532","article-title":"Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy","volume":"43","author":"Kissel JT","year":"1993","journal-title":"Neurology"},{"issue":"3Pt1","key":"ref43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.43.3_Part_1.527","article-title":"Cyclosporine increases muscular force generation in Duchenne muscular dystrophy","volume":"43","author":"Sharma KR","year":"1993","journal-title":"Neurology"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1474-4422(10)70196-4","article-title":"Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial","volume":"9","author":"Kirschner J","year":"2010","journal-title":"Lancet Neurol"},{"issue":"7894","key":"ref45","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","article-title":"Prednisone in Duchenne muscular dystrophy","volume":"2","author":"Drachman DB","year":"1974","journal-title":"Lancet"},{"issue":"24","key":"ref46","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell JR","year":"1989","journal-title":"N Engl J Med"},{"issue":"10119","key":"ref47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"CINRG Investigators. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald CM","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/archdischild-2015-308654","article-title":"Short stature and pubertal delay in Duchenne muscular dystrophy","volume":"101","author":"Wood CL","year":"2016","journal-title":"Arch Dis Child"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0111-8","article-title":"Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids","volume":"18","author":"Parente L","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.26191","article-title":"THE ACT DMD STUDY GROUP. Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial","volume":"58","author":"Shieh PB","year":"2018","journal-title":"Muscle Nerve"},{"issue":"5692","key":"ref51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/277146a0","article-title":"Phenotypic suppression and misreading Saccharomyces cerevisiae","volume":"277","author":"Singh A","year":"1979","journal-title":"Nature"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1172\/JCI7866","article-title":"Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice","volume":"104","author":"Barton-Davis ER","year":"1999","journal-title":"J Clin Invest"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.1023","article-title":"Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations","volume":"49","author":"Wagner KR","year":"2001","journal-title":"Ann Neurol"},{"issue":"6","key":"ref54","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy","volume":"67","author":"Malik V","year":"2010","journal-title":"Ann Neurol"},{"issue":"44","key":"ref55","doi-asserted-by":"crossref","first-page":"12353","DOI":"10.1073\/pnas.1615548113","article-title":"Proposing a mechanism of action for ataluren","volume":"13","author":"Siddiqui N","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"ref56","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"PTC124-GD-007-DMD STUDY GROUP. Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby K","year":"2014","journal-title":"Muscle Nerve"},{"issue":"10101","key":"ref57","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Clinical Evaluator Training Group; ACT DMD Study Group. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald CM","year":"2017","journal-title":"Lancet"},{"key":"ref58","first-page":"1","article-title":"Antisense oligonucleotide in neurological disorders","volume":"11","author":"Wurster CD","year":"2018","journal-title":"Ther Adv Neurol Disorder"},{"issue":"8","key":"ref59","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm897","article-title":"Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse","volume":"9","author":"Lu QL","year":"2003","journal-title":"Nat Med"},{"issue":"8","key":"ref60","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/acn3.579","article-title":"DEMAND V study group. Placebocontrolled phase 2 trial of drisapersen for Duchenne muscular dystrophy","volume":"5","author":"McDonald CM","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"ref61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"DEMAND III study group. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"Goemans N","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"ref62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Eteplirsen Study Group and Telethon Foundation DMD Italian Network. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell JR","year":"2016","journal-title":"Ann Neurol"},{"issue":"24","key":"ref63","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston JS","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"ref64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13023-018-0834-2","article-title":"Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"13","author":"Shimizu-Motohashi Y","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"ref65","article-title":"Emerging drugs for Duchenne muscular dystrophy","author":"Shawi F","year":"2017","journal-title":"Issues Emerg Health Technol. 2016-16"},{"issue":"11","key":"ref66","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s10072-018-3555-3","article-title":"Clinical management of Duchenne muscular dystrophy: the state of the art","volume":"39","author":"Messina S","year":"2018","journal-title":"Neurol Sci"},{"issue":"3","key":"ref67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant DJ","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"ref68","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nmd.2014.09.003","article-title":"Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy","volume":"25","author":"Lynn S","year":"2015","journal-title":"Neuromuscul Disord"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v77n8\/1678-4227-anp-77-08-0579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T23:44:15Z","timestamp":1721691855000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2019000800579&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":68,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["S0004-282X2019000800579"],"URL":"https:\/\/doi.org\/10.1590\/0004-282x20190088","relation":{},"ISSN":["1678-4227","0004-282X"],"issn-type":[{"value":"1678-4227","type":"electronic"},{"value":"0004-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}